March 6, 2026 | Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, explore how initial treatment choice impacts subsequent sequencing strategies in EGFR-mutated NSCLC. Neal highlights resistance mechanisms that emerge after frontline targeted therapy and their implications for later-line options. Goldberg discusses the importance of repeat molecular testing and adapting therapy based on evolving tumor biology.
Related Posts
Factors Driving Frontline Treatment Selection in EGFR-Mutated NSCLC
Navigating Treatment Decisions for EGFR-Mutated NSCLC With High-Risk Features
The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management
AE Management With Subcutaneous Amivantamab in EGFR-Mutated NSCLC
